| __timestamp | Bausch Health Companies Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 612613000000 |
| Thursday, January 1, 2015 | 2682700000 | 650773000000 |
| Friday, January 1, 2016 | 2810000000 | 619061000000 |
| Sunday, January 1, 2017 | 2582000000 | 628106000000 |
| Monday, January 1, 2018 | 2473000000 | 717599000000 |
| Tuesday, January 1, 2019 | 2554000000 | 964737000000 |
| Wednesday, January 1, 2020 | 2367000000 | 875663000000 |
| Friday, January 1, 2021 | 2624000000 | 886361000000 |
| Saturday, January 1, 2022 | 2625000000 | 997309000000 |
| Sunday, January 1, 2023 | 2917000000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry titans: Takeda Pharmaceutical Company Limited and Bausch Health Companies Inc., from 2014 to 2023.
Takeda's SG&A expenses have shown a remarkable upward trajectory, growing by approximately 72% over the decade. This reflects their strategic investments in global expansion and innovation, culminating in a peak of over 1 trillion yen in 2023.
Conversely, Bausch Health's SG&A expenses have remained relatively stable, with a modest increase of around 44% over the same period. This stability underscores their focus on maintaining operational efficiency amidst market challenges.
The data highlights the contrasting strategies of these pharmaceutical giants, offering valuable insights into their financial stewardship.
Comparing SG&A Expenses: Johnson & Johnson vs Bausch Health Companies Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc. Trends and Insights
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?